IBDEI0Q6 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12863,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12863,1,1,0)
 ;;=1^569.9
 ;;^UTILITY(U,$J,358.3,12863,1,2,0)
 ;;=2^OTHER INTESTINAL COND
 ;;^UTILITY(U,$J,358.3,12863,2)
 ;;=^123842
 ;;^UTILITY(U,$J,358.3,12864,0)
 ;;=573.9^^75^795^21
 ;;^UTILITY(U,$J,358.3,12864,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12864,1,1,0)
 ;;=1^573.9
 ;;^UTILITY(U,$J,358.3,12864,1,2,0)
 ;;=2^OTHER LIVER DISEASE
 ;;^UTILITY(U,$J,358.3,12864,2)
 ;;=^123854
 ;;^UTILITY(U,$J,358.3,12865,0)
 ;;=580.9^^75^796^1
 ;;^UTILITY(U,$J,358.3,12865,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12865,1,1,0)
 ;;=1^580.9
 ;;^UTILITY(U,$J,358.3,12865,1,2,0)
 ;;=2^ACUTE GLOMERULONEPHRITIS
 ;;^UTILITY(U,$J,358.3,12865,2)
 ;;=^270342
 ;;^UTILITY(U,$J,358.3,12866,0)
 ;;=584.9^^75^796^2
 ;;^UTILITY(U,$J,358.3,12866,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12866,1,1,0)
 ;;=1^584.9
 ;;^UTILITY(U,$J,358.3,12866,1,2,0)
 ;;=2^ACUTE RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,12866,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,12867,0)
 ;;=582.9^^75^796^3
 ;;^UTILITY(U,$J,358.3,12867,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12867,1,1,0)
 ;;=1^582.9
 ;;^UTILITY(U,$J,358.3,12867,1,2,0)
 ;;=2^CHRONIC GLOMERULONEPHRITIS
 ;;^UTILITY(U,$J,358.3,12867,2)
 ;;=^270351
 ;;^UTILITY(U,$J,358.3,12868,0)
 ;;=585.9^^75^796^4
 ;;^UTILITY(U,$J,358.3,12868,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12868,1,1,0)
 ;;=1^585.9
 ;;^UTILITY(U,$J,358.3,12868,1,2,0)
 ;;=2^CHRONIC KIDNEY DISEASE
 ;;^UTILITY(U,$J,358.3,12868,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,12869,0)
 ;;=586.^^75^796^5
 ;;^UTILITY(U,$J,358.3,12869,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12869,1,1,0)
 ;;=1^586.
 ;;^UTILITY(U,$J,358.3,12869,1,2,0)
 ;;=2^OTHER RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,12869,2)
 ;;=^104733
 ;;^UTILITY(U,$J,358.3,12870,0)
 ;;=694.9^^75^797^1
 ;;^UTILITY(U,$J,358.3,12870,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12870,1,1,0)
 ;;=1^694.9
 ;;^UTILITY(U,$J,358.3,12870,1,2,0)
 ;;=2^BULLOUS DERMATOSES NOS
 ;;^UTILITY(U,$J,358.3,12870,2)
 ;;=^187900
 ;;^UTILITY(U,$J,358.3,12871,0)
 ;;=695.10^^75^797^2
 ;;^UTILITY(U,$J,358.3,12871,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12871,1,1,0)
 ;;=1^695.10
 ;;^UTILITY(U,$J,358.3,12871,1,2,0)
 ;;=2^ERYTHEMA MULTIFORME NOS
 ;;^UTILITY(U,$J,358.3,12871,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,12872,0)
 ;;=696.1^^75^797^3
 ;;^UTILITY(U,$J,358.3,12872,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12872,1,1,0)
 ;;=1^696.1
 ;;^UTILITY(U,$J,358.3,12872,1,2,0)
 ;;=2^PSORIASIS
 ;;^UTILITY(U,$J,358.3,12872,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,12873,0)
 ;;=695.81^^75^797^4
 ;;^UTILITY(U,$J,358.3,12873,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12873,1,1,0)
 ;;=1^695.81
 ;;^UTILITY(U,$J,358.3,12873,1,2,0)
 ;;=2^STAPHLYCOCCAL SCALED SKIN SYND
 ;;^UTILITY(U,$J,358.3,12873,2)
 ;;=^113858
 ;;^UTILITY(U,$J,358.3,12874,0)
 ;;=695.13^^75^797^5
 ;;^UTILITY(U,$J,358.3,12874,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12874,1,1,0)
 ;;=1^695.13
 ;;^UTILITY(U,$J,358.3,12874,1,2,0)
 ;;=2^STEVENS-JOHNSON SYNDROME
 ;;^UTILITY(U,$J,358.3,12874,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,12875,0)
 ;;=695.15^^75^797^6
 ;;^UTILITY(U,$J,358.3,12875,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12875,1,1,0)
 ;;=1^695.15
 ;;^UTILITY(U,$J,358.3,12875,1,2,0)
 ;;=2^TOXIC EPIDRML NECROLYSIS
 ;;^UTILITY(U,$J,358.3,12875,2)
 ;;=^336638
 ;;^UTILITY(U,$J,358.3,12876,0)
 ;;=695.9^^75^797^7
 ;;^UTILITY(U,$J,358.3,12876,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12876,1,1,0)
 ;;=1^695.9
 ;;^UTILITY(U,$J,358.3,12876,1,2,0)
 ;;=2^OTHER ERYTHEMATOUS SKIN COND
 ;;^UTILITY(U,$J,358.3,12876,2)
 ;;=^123902
